Serum FGF2 levels in MDD patients were significantly lower than those in healthy controls (p = 0.005), and the serum FGF2 levels decreased significantly but marginally following treatment for 8 weeks (p = 0.005). The gene discussed is FGF2; the disease is major depressive disorder.